Document Type : Original Article(s)


1 Professor, Atherosclerosis Research Center, Baqiyatallah University of Medical Sciences, Tehran, Iran

2 Resident, Isfahan Cardiovascular Research Center, Cardiovascular Research Institute, Isfahan University of Medical Sciences, Isfahan, Iran

3 Professor, Cardiac Rehabilitation Research Center, Cardiovascular Research Institute, Isfahan University of Medical Sciences, Isfahan, Iran

4 Professor, Isfahan Cardiovascular Research Center, Cardiovascular Research Institute, Isfahan University of Medical Sciences, Isfahan, Iran

5 Assistant Professor, Atherosclerosis Research Center, Baqiyatallah University of Medical Sciences, Tehran, Iran

6 Research Assistant, Cardiovascular Research Institute, Isfahan University of Medical Sciences, Isfahan, Iran

7 Assistant Professor, Isfahan Cardiovascular Research Center, Cardiovascular Research Institute, Isfahan University of Medical Sciences, Isfahan AND Department of Neurology, School of Medicine, Tehran University of Medical Sciences, Tehran, Iran


BACKGROUND: Numerous studies have been conducted on the predictive effects of high-sensitivity C-reactive protein (hs-CRP) on cardiovascular events. Few studies have been conducted to investigate the effects of adiponectin for the prediction of the incident of cardiovascular events in the Middle East area. This study compared the predictive effect of hs-CRP and adiponectin on healthy volunteers for the prediction of cerebrovascular disease (CVD). METHODS: This nested case-control in original Isfahan Cohort Study (ICS) was conducted from 2001 to 2011. Participants were selected from ICS. The case group included participants with CVD while the control group included participants without CVD. The level of hs-CRP and adiponectin was measured in the blood samples collected in the year 2007. Thereafter, the statistical analyses were performed to determine the predictive value of hs-CRP and adiponectin in CVD prediction. RESULTS: The results showed that before the elimination of diabetes effect; there was a significant difference between the two groups, in terms of the mean of adiponectin (P = 0.019) and no significant difference was observed in hs-CRP levels (P = 0.673). However, after eliminating the factor of diabetes, there was no significant difference between the case and control groups in adiponectin and hs-CRP levels (P = 0.184, P = 0.946). The results showed that the odds ratio (OR) of the adiponectin level was 0.879 [95% confidence interval (CI): 0.719-1.075, P = 0.210] while the OR of hs-CRP was 1.045 (95% CI: 0.922-1.185, P = 0.491). Furthermore, it was shown that after adjustment for age, sex, and diabetes; the OR of adiponectine was 0.875 (95% CI: 0.701-1.091, P = 0.235) and that of hs-CRP was 1.068 (95% CI: 0.935-1.219, P = 0.333). CONCLUSION: The results show that adiponectin and hs-CRP cannot be predictors for cardiovascular events in a healthy population. Risk factors such as diabetes limit the use of adiponectin as a CVD predictor. 


  1. Gersh BJ, Sliwa K, Mayosi BM, Yusuf S. Novel therapeutic concepts: the epidemic of cardiovascular disease in the developing world: global implications. Eur Heart J 2010; 31(6): 642-8.
  2. Talaei M, Sarrafzadegan N, Sadeghi M, Oveisgharan S, Marshall T, Thomas GN, et al. Incidence of cardiovascular diseases in an Iranian population: the Isfahan Cohort Study. Arch Iran Med 2013; 16(3): 138-44.
  3. Funahashi T, Nakamura T, Shimomura I, Maeda K, Kuriyama H, Takahashi M, et al. Role of adipocytokines on the pathogenesis of atherosclerosis in visceral obesity. Intern Med 1999; 38(2): 202-6.
  4. Talaei M, Sadeghi M, Marshall T, Thomas GN, Kabiri P, Hoseini S, et al. Impact of metabolic syndrome on ischemic heart disease - a prospective cohort study in an Iranian adult population: Isfahan Cohort Study. Nutr Metab Cardiovasc Dis 2012; 22(5): 434-41.
  5. Havel PJ. Control of energy homeostasis and insulin action by adipocyte hormones: leptin, acylation stimulating protein, and adiponectin. Curr Opin Lipidol 2002; 13(1): 51-9.
  6. Lindsay RS, Funahashi T, Hanson RL, Matsuzawa Y, Tanaka S, Tataranni PA, et al. Adiponectin and development of type 2 diabetes in the Pima Indian population. Lancet 2002; 360(9326): 57-8.
  7. Scherer PE, Williams S, Fogliano M, Baldini G, Lodish HF. A novel serum protein similar to C1q, produced exclusively in adipocytes. J Biol Chem 1995; 270(45): 26746-9.
  8. Kishore U, Reid KB. C1q: structure, function, and receptors. Immunopharmacology 2000; 49(1-2): 159-70.
  9. Hu E, Liang P, Spiegelman BM. AdipoQ is a novel adipose-specific gene dysregulated in obesity. J Biol Chem 1996; 271(18): 10697-703.
  10. Weyer C, Funahashi T, Tanaka S, Hotta K, Matsuzawa Y, Pratley RE, et al. Hypoadiponectinemia in obesity and type 2 diabetes: close association with insulin resistance and hyperinsulinemia. J Clin Endocrinol Metab 2001; 86(5): 1930-5.
  11. Khaledi Y, Aghababaei E, Sadeghi M, Hashemi M, Sanei H. Evaluation of heart rate reserve and high-sensitivity C-reactive protein in individuals with and without metabolic syndrome in Isfahan, Iran. ARYA Atheroscler 2012; 8(2): 70-5.
  12. Kishida K, Funahashi T, Shimomura I. Adiponectin as a routine clinical biomarker. Best Pract Res Clin Endocrinol Metab 2014; 28(1): 119-30.
  13. Clearfield MB. C-reactive protein: a new risk assessment tool for cardiovascular disease. J Am Osteopath Assoc 2005; 105(9): 409-16.
  14. Giffen PS, Turton J, Andrews CM, Barrett P, Clarke CJ, Fung KW, et al. Markers of experimental acute inflammation in the Wistar Han rat with particular reference to haptoglobin and C-reactive protein. Arch Toxicol 2003; 77(7): 392-402.
  15. Luc G, Bard JM, Juhan-Vague I, Ferrieres J, Evans A, Amouyel P, et al. C-reactive protein, interleukin-6, and fibrinogen as predictors of coronary heart disease: the PRIME Study. Arterioscler Thromb Vasc Biol 2003; 23(7): 1255-61.
  16. Choobineh S, Dabidy Roshan V, Gaieni AA. Effect of the continues and intermittence aerobic training on high - sensitive c-reactive protein in rats. Journal of Movement Science and Sport 2007; 5(9): 1-14. [In Persian].
  17. Baptista S, Piloto N, Reis F, Teixeira-de-Lemos E, Garrido AP, Dias A, et al. Treadmill running and swimming imposes distinct cardiovascular physiological adaptations in the rat: focus on serotonergic and sympathetic nervous systems modulation. Acta Physiol Hung 2008; 95(4): 365-81.
  18. Hotta K, Funahashi T, Arita Y, Takahashi M, Matsuda M, Okamoto Y, et al. Plasma concentrations of a novel, adipose-specific protein, adiponectin, in type 2 diabetic patients. Arterioscler Thromb Vasc Biol 2000; 20(6): 1595-9.
  19. Fasshauer M, Klein J, Neumann S, Eszlinger M, Paschke R. Hormonal regulation of adiponectin gene expression in 3T3-L1 adipocytes. Biochem Biophys Res Commun 2002; 290(3): 1084-9.
  20. Kappes A, Loffler G. Influences of ionomycin, dibutyryl-cycloAMP and tumour necrosis factor-alpha on intracellular amount and secretion of apM1 in differentiating primary human preadipocytes. Horm Metab Res 2000; 32(11-12): 548-54.
  21. Kumada M, Kihara S, Sumitsuji S, Kawamoto T, Matsumoto S, Ouchi N, et al. Association of hypoadiponectinemia with coronary artery disease in men. Arterioscler Thromb Vasc Biol 2003; 23(1): 85-9.
  22. Sarrafzadegan N, Talaei M, Sadeghi M, Kelishadi R, Oveisgharan S, Mohammadifard N, et al. The Isfahan cohort study: rationale, methods and main findings. J Hum Hypertens 2011; 25(9): 545-53.
  23. Sadeghi M, Talaei M, Zand I, Oveisgharan S, Iranipour R, Esteki GF, et al. Heart rate and cardiovascular events: a nested case-control in Isfahan Cohort Study. Arch Iran Med 2014; 17(9): 633-7.
  24. Oliveira GB, Franca JI, Piegas LS. Serum adiponectin and cardiometabolic risk in patients with acute coronary syndromes. Arq Bras Cardiol 2013; 101(5): 399-409.
  25. Kawagoe J, Ishikawa T, Iwakiri H, Date H, Imamura T, Kitamura K. Association between adiponectin production in coronary circulation and future cardiovascular events in patients with coronary artery disease. Int Heart J 2014; 55(3): 239-43.
  26. Kuwashiro T, Ago T, Kamouchi M, Matsuo R, Hata J, Kuroda J, et al. Significance of plasma adiponectin for diagnosis, neurological severity and functional outcome in ischemic stroke-Research for Biomarkers in Ischemic Stroke (REBIOS). Metabolism 2014; 63(9): 1093-103.
  27. Pera J, Dziedzic T, Szczudlik A, Slowik A. Temporal changes of adiponectin plasma levels in patients with acute ischemic stroke. Neurol Res 2013; 35(9): 988-91.
  28. Arregui M, Buijsse B, Fritsche A, di Giuseppe R, Schulze MB, Westphal S, et al. Adiponectin and risk of stroke: prospective study and meta-analysis. Stroke 2014; 45(1): 10-7.
  29. Lindberg S, Jensen JS, Bjerre M, Pedersen SH, Frystyk J, Flyvbjerg A, et al. Adiponectin, type 2 diabetes and cardiovascular risk. Eur J Prev Cardiol 2015; 22(3): 276-83.
  30. Bidulescu A, Liu J, Chen Z, Hickson DA, Musani SK, Samdarshi TE, et al. Associations of adiponectin and leptin with incident coronary heart disease and ischemic stroke in african americans: the jackson heart study. Front Public Health 2013; 1: 16.
  31. Ridker PM, Cushman M, Stampfer MJ, Tracy RP, Hennekens CH. Inflammation, aspirin, and the risk of cardiovascular disease in apparently healthy men. N Engl J Med 1997; 336(14): 973-9.